A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin. 1995

R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
Department of Obstetrics and Gynecology, Golda Meir Medical Center, Hasharon Hospital, Petah Tikva, Israel.

OBJECTIVE To evaluate the role of the recently suggested IV administration of human albumin solution as an effective preventive measure of severe ovarian hyperstimulation in high-risk patients. METHODS Presented here is, to the best of our knowledge, the first case of early severe ovarian hyperstimulation necessitating early transabdominal aspiration of ascites and intensive fluid and colloid (dextran and albumin) replacement, which developed despite administration of IV human albumin solution in an attempt to prevent severe ovarian hyperstimulation. CONCLUSIONS Because IV albumin does not prevent severe ovarian hyperstimulation in absolute terms, its use in high-risk patients should not lead one astray. Further research should be directed at investigating the fundamental cause of ovarian hyperstimulation syndrome and developing a reliable predictive test for this complication.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D003911 Dextrans A group of glucose polymers made by certain bacteria. Dextrans are used therapeutically as plasma volume expanders and anticoagulants. They are also commonly used in biological experimentation and in industry for a wide variety of purposes. Dextran,Dextran 40,Dextran 40000,Dextran 70,Dextran 75,Dextran 80,Dextran B-1355,Dextran B-1355-S,Dextran B1355,Dextran B512,Dextran Derivatives,Dextran M 70,Dextran T 70,Dextran T-40,Dextran T-500,Hemodex,Hyskon,Infukoll,Macrodex,Polyglucin,Promit,Rheodextran,Rheoisodex,Rheomacrodex,Rheopolyglucin,Rondex,Saviosol,Dextran B 1355,Dextran B 1355 S,Dextran T 40,Dextran T 500
D005260 Female Females
D005440 Fluid Therapy Therapy whose basic objective is to restore the volume and composition of the body fluids to normal with respect to WATER-ELECTROLYTE BALANCE. Fluids may be administered intravenously, orally, by intermittent gavage, or by HYPODERMOCLYSIS. Oral Rehydration Therapy,Rehydration,Rehydration, Oral,Oral Rehydration,Rehydration Therapy, Oral,Therapy, Fluid,Therapy, Oral Rehydration,Fluid Therapies,Oral Rehydration Therapies,Oral Rehydrations,Rehydration Therapies, Oral,Rehydrations,Rehydrations, Oral,Therapies, Fluid,Therapies, Oral Rehydration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001201 Ascites Accumulation or retention of free fluid within the peritoneal cavity.
D001239 Inhalation The act of BREATHING in. Inhaling,Inspiration, Respiratory,Respiratory Inspiration
D012709 Serum Albumin A major protein in the BLOOD. It is important in maintaining the colloidal osmotic pressure and transporting large organic molecules. Plasma Albumin,Albumin, Serum
D016471 Ovarian Hyperstimulation Syndrome A complication of OVULATION INDUCTION in infertility treatment. It is graded by the severity of symptoms which include OVARY enlargement, multiple OVARIAN FOLLICLES; OVARIAN CYSTS; ASCITES; and generalized EDEMA. The full-blown syndrome may lead to RENAL FAILURE, respiratory distress, and even DEATH. Increased capillary permeability is caused by the vasoactive substances, such as VASCULAR ENDOTHELIAL GROWTH FACTORS, secreted by the overly-stimulated OVARIES. Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous,Hyperstimulation Syndrome, Ovarian,Hyperstimulation Syndromes, Ovarian,Ovarian Hyperstimulation Syndromes

Related Publications

R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
February 1996, Human reproduction (Oxford, England),
R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
October 1996, Fertility and sterility,
R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
November 1997, Fertility and sterility,
R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
February 1999, Fertility and sterility,
R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
November 1994, Human reproduction (Oxford, England),
R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
July 1997, Fertility and sterility,
R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
January 2011, Fertility and sterility,
R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
December 2002, Human reproduction (Oxford, England),
R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
December 1998, Human reproduction (Oxford, England),
R Orvieto, and A Dekel, and D Dicker, and I Bar-Hava, and Z Ben-Rafael
August 1997, Fertility and sterility,
Copied contents to your clipboard!